Literature DB >> 21425100

[Demyelinating disease and vaccination of the human papillomavirus].

M Josefa Álvarez-Soria1, Amalia Hernández-González, Sira Carrasco-García de León, M Ángeles del Real-Francia, M José Gallardo-Alcañiz, José L López-Gómez.   

Abstract

INTRODUCTION: Primary prevention by prophylactic vaccination against the major cause of cervical cancer, the carcinogenic human papillomavirus (HPV) types 16 and 18, is now available worldwide. Postlicensure adverse neurological effects have been described. The studies realized after the license are descriptive and limited by the difficulty to obtain the information, despite most of the statistical indexes show that the adverse effects by the vaccine of the HPV are not upper compared with other vaccines, the substimation must be considered. CASE REPORTS: We describe the cases of four young women that developed demyelinating disease after the vaccination of the HPV, with a rank of time between the administration of the dose and the development of the clinical of seven days to a month, with similar symptoms with the successive doses. We have described six episodes coinciding after the vaccination.
CONCLUSIONS: Have been described seizures, autoimmune disorders such as Guillain-Barre syndrome, transverse myelitis, or motor neuron disease, probably adverse effects following immunization by HPV vaccine. So we suggest that vaccine may trigger an immunological mechanism leading to demyelinating events, perhaps in predisposed young.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425100

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

1.  Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018.

Authors:  G Gross; N Becker; N H Brockmeyer; S Esser; U Freitag; M Gebhardt; L Gissmann; P Hillemanns; H Grundhewer; H Ikenberg; H Jessen; A Kaufmann; S Klug; J P Klußmann; A Nast; D Pathirana; K U Petry; H Pfister; U Röllinghof; P Schneede; A Schneider; E Selka; S Singer; S Smola; B Sporbeck; M von Knebel Doeberitz; P Wutzler
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

Review 2.  Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity.

Authors:  Abdulla Watad; Paula David; Stav Brown; Yehuda Shoenfeld
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-24       Impact factor: 5.555

Review 3.  Is aluminum exposure a risk factor for neurological disorders?

Authors:  Elif Inan-Eroglu; Aylin Ayaz
Journal:  J Res Med Sci       Date:  2018-06-06       Impact factor: 1.852

Review 4.  Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis.

Authors:  Mahin Khatami
Journal:  Clin Transl Med       Date:  2020-12

5.  Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion.

Authors:  B Pla Peris; A Á Merchante Alfaro; F J Maravall Royo; P Abellán Galiana; S Pérez Naranjo; M González Boillos
Journal:  J Endocrinol Invest       Date:  2022-01-11       Impact factor: 5.467

6.  Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.

Authors:  Rotem Inbar; Ronen Weiss; Lucija Tomljenovic; Maria-Teresa Arango; Yael Deri; Christopher A Shaw; Joab Chapman; Miri Blank; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

7.  Influenza vaccine-induced CNS demyelination in a 50-year-old male.

Authors:  Aaron Sacheli; Raymond Bauer
Journal:  Am J Case Rep       Date:  2014-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.